Neos Therapeutics Inc Revenue Growth Rates (NEOS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Neos Therapeutics Inc   (NASDAQ: NEOS)
 

NEOS's Revenue Growth by Quarter and Year

Neos Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NEOS Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September 12.54
2nd Quarter June 13.13
1st Quarter March 14.49
FY 40.16

NEOSs Annual Revenue
Neos Therapeutics Inc 's Revenue in the fiscal year 2019 $ 64.65 millions
Neos Therapeutics Inc 's Revenue in the fiscal year 2018 $ 49.99 millions
Neos Therapeutics Inc 's Revenue in the fiscal year 2017 $ 25.02 millions
Neos Therapeutics Inc 's Revenue in the fiscal year 2016 $ 9.15 millions
Neos Therapeutics Inc 's Revenue in the fiscal year 2015 $ 3.79 millions




NEOS Revenue third quarter 2020 Y/Y Growth Comment
Neos Therapeutics Inc reported fall in Revenue in the third quarter 2020 by -28.53% to $ 12.54 millions, from the same quarter in 2019.
This represents worst decline in recent Company history.

Looking into third quarter 2020 results within Major Pharmaceutical Preparations industry 189 other companies have achieved higher Revenue growth. While Neos Therapeutics Inc ' s Revenue drop of -28.53% ranks overall at the positon no. 3293 in the third quarter 2020.


NEOS Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 9.36 % 97.56 % 122.57 %
3rd Quarter September -28.53 % 40.32 % 86.57 % 324.05 %
2nd Quarter June -16.05 % 37.68 % 131.36 % 229.53 %
1st Quarter March -0.96 % 36.35 % 90.59 % 118.22 %
FY   - 29.33 % 99.68 % -

Financial Statements
Neos Therapeutics Inc 's third quarter 2020 Revenue $ 12.54 millions NEOS's Income Statement
Neos Therapeutics Inc 's third quarter 2019 Revenue $ 17.54 millions Quarterly NEOS's Income Statement


NEOS Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - -4.05 % 23.12 % 16.27 %
3rd Quarter September -4.53 % 12.15 % 10.04 % 36.46 %
2nd Quarter June -9.39 % 6.9 % 5.87 % -12.79 %
1st Quarter March -13.9 % -4.94 % 37.74 % 60.86 %
FY (Year on Year)   - 29.33 % 99.68 % -


Back to NEOS Growth rate Comparisons >> Back to NEOS Growth rate Comparisons >>


Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #190
Healthcare Sector #498
Overall #3293

Revenue Y/Y Growth Statistics
High Average Low
616.29 % 111.45 % -28.53 %
(Mar 31 2017)   (Sep 30 2020)
Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #190
Healthcare Sector #498
Overall #3293
Revenue Y/Y Growth Statistics
High Average Low
616.29 % 111.45 % -28.53 %
(Mar 31 2017)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Neos Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
121.29 % 8.42 % -85.11 %
(Dec 31 2016)  


NEOS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2020 Neos Therapeutics Inc disclosed fall in Revenue from the second quarter by -4.53% to $ 12.54 millions, from $ 13.13 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2020 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Revenue quarter on quarter growth. While Neos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3378.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #498
Overall #3378
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #498
Overall #3378
Revenue Q/Q Growth Statistics
High Average Low
121.29 % 8.42 % -85.11 %
(Dec 31 2016)  


NEOS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2020 Neos Therapeutics Inc disclosed fall in Revenue from the second quarter by -4.53% to $ 12.54 millions, from $ 13.13 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2020 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Revenue quarter on quarter growth. While Neos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3378.


Neos Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)
Cumulative Revenue 12 Months Ending $ 56.99 $ 62.00 $ 64.51 $ 64.65 $ 63.21
Y / Y Revenue Growth (TTM) -9.84 % 6.58 % 19.7 % 29.33 % 49.14 %
Year on Year Revenue Growth Overall Ranking # 364 # 1079 # 627 # 241 # 2448
Seqeuential Revenue Change (TTM) -8.07 % -3.89 % -0.22 % 2.28 % 8.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 1057 # 1981 # 1700 # 415 # 770


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2020 Neos Therapeutics Inc reported a decrease in Revenue by -9.84% year on year, to $57 millions, compare to the 6.58% growth at Jun 30 2020.

In the Healthcare sector 122 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 364, from total ranking in previous quarter at 1079.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 94
Healthcare Sector # 123
Overall # 364

Revenue TTM Y/Y Growth Statistics
High Average Low
565.21 %
 139.52 %
-9.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 94
Sector # 204
S&P 500 # 1057
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2020 Neos Therapeutics Inc reported a decrease in Revenue by -9.84% year on year, to $57 millions, compare to the 6.58% growth at Jun 30 2020.

In the Healthcare sector 122 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 364, from total ranking in previous quarter at 1079.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 94
Healthcare Sector # 123
Overall # 364

Revenue TTM Y/Y Growth Statistics
High Average Low
565.21 %
139.52 %
-9.84 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 94
Sector # 204
S&P 500 # 1057




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NEOS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2020
Ensign Group Inc-0.21%$ -0.208 millions
Crh Medical Corporation-0.21%$ -0.215 millions
Radnet Inc -0.24%$ -0.237 millions
Tenet Healthcare Corp-0.24%$ -0.241 millions
Prestige Consumer Healthcare Inc -0.27%$ -0.272 millions
Establishment Labs Holdings Inc -0.42%$ -0.420 millions
Cocrystal Pharma Inc -0.61%$ -0.610 millions
American Renal Associates Holdings Inc -0.82%$ -0.823 millions
Rockwell Medical inc -0.83%$ -0.826 millions
Tactile Systems Technology Inc -1.05%$ -1.048 millions
Icon Plc-1.23%$ -1.226 millions
American Bio Medica Corporation-1.34%$ -1.341 millions
Transmedics Group Inc -1.58%$ -1.582 millions
Boston Scientific Corporation-1.77%$ -1.773 millions
Bruker Corporation-1.86%$ -1.861 millions
Orthofix Medical Inc -2.21%$ -2.215 millions
Encision Inc -2.29%$ -2.288 millions
Integra Lifesciences Holdings Corp-2.34%$ -2.338 millions
Neurometrix Inc -2.48%$ -2.480 millions
Lifevantage Corp-2.49%$ -2.492 millions
Macrogenics Inc -2.60%$ -2.604 millions
Surgalign Holdings Inc -2.70%$ -2.704 millions
Alimera Sciences Inc-2.93%$ -2.934 millions
Fortress Biotech Inc -3.04%$ -3.039 millions
Teleflex Incorporated-3.09%$ -3.088 millions
Adm Tronics Unlimited Inc -3.10%$ -3.105 millions
Bausch Health Companies Inc -3.21%$ -3.214 millions
Atricure Inc -3.28%$ -3.280 millions
Aspira Women s Health inc -3.58%$ -3.580 millions
Electromed Inc -3.59%$ -3.593 millions


About Neos Therapeutics Inc Revenue Growth Rates (NEOS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.